DE69733204D1 - Neuartige vegf-ähnliche faktoren - Google Patents

Neuartige vegf-ähnliche faktoren

Info

Publication number
DE69733204D1
DE69733204D1 DE69733204T DE69733204T DE69733204D1 DE 69733204 D1 DE69733204 D1 DE 69733204D1 DE 69733204 T DE69733204 T DE 69733204T DE 69733204 T DE69733204 T DE 69733204T DE 69733204 D1 DE69733204 D1 DE 69733204D1
Authority
DE
Germany
Prior art keywords
vegf
gene
isolated
protein
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69733204T
Other languages
English (en)
Other versions
DE69733204T2 (de
DE69733204T3 (de
Inventor
Yuichi Hirata
Junichi Nezu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16166915&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69733204(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of DE69733204D1 publication Critical patent/DE69733204D1/de
Publication of DE69733204T2 publication Critical patent/DE69733204T2/de
Application granted granted Critical
Publication of DE69733204T3 publication Critical patent/DE69733204T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69733204T 1996-07-15 1997-07-15 Neuartige vegf-ähnliche faktoren Expired - Lifetime DE69733204T3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP18521696 1996-07-15
JP18521696 1996-07-15
PCT/JP1997/002456 WO1998002543A1 (fr) 1996-07-15 1997-07-15 Nouveaux facteurs analogues au vegf
EP97930804A EP0935001B2 (de) 1996-07-15 1997-07-15 Neuartige vegf-ähnliche faktoren

Publications (3)

Publication Number Publication Date
DE69733204D1 true DE69733204D1 (de) 2005-06-09
DE69733204T2 DE69733204T2 (de) 2006-05-11
DE69733204T3 DE69733204T3 (de) 2012-03-08

Family

ID=16166915

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69733204T Expired - Lifetime DE69733204T3 (de) 1996-07-15 1997-07-15 Neuartige vegf-ähnliche faktoren

Country Status (8)

Country Link
US (4) US6828426B1 (de)
EP (1) EP0935001B2 (de)
JP (1) JP3911028B2 (de)
AT (1) ATE294863T1 (de)
AU (1) AU733322B2 (de)
DE (1) DE69733204T3 (de)
ES (1) ES2242227T5 (de)
WO (1) WO1998002543A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
EP1382679A3 (de) * 1995-09-08 2004-11-10 Genentech, Inc. Antagonisten gegen Vaskuläres Endothelzellen Wachstumsfaktor-verwandtes Protein (VRP)
EP1553182B1 (de) 1995-09-29 2010-03-03 Universita Degli Studi Di Siena Regulierte Gene und ihre Verwendungen
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US6828426B1 (en) 1996-07-15 2004-12-07 Chugai Seiyaku Kabushiki Kaisha VEGF-like factor
DK0956339T3 (da) * 1996-08-23 2006-01-30 Licentia Oy Rekombinant vaskulær endotelcellevækstfaktor D (VEGF-D)
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DE69839529D1 (de) * 1997-12-24 2008-07-03 Ludwig Inst Cancer Res Expressionsvektoren und zellinien zur expression von vaskulärem wachstumsfaktor d, sowie verfahren zur behandlung von melanomen
US6958147B1 (en) * 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
CN1330555A (zh) * 1998-12-21 2002-01-09 路德维格癌症研究所 抗截短的vegf－d的抗体及其应用
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
AU3501700A (en) 1999-02-26 2000-09-14 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US6764820B2 (en) * 1999-03-26 2004-07-20 Ludwig Institute For Cancer Research Screening for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3)
DE60131146T2 (de) 2000-02-25 2008-03-06 Ludwig Institute For Cancer Research Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren
US20020102260A1 (en) 2000-03-02 2002-08-01 Marc Achen Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
AU2006201128B2 (en) * 2000-03-02 2009-05-28 Vegenics Limited Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor D
DK1259248T3 (da) * 2000-03-02 2005-04-11 Ludwig Inst Cancer Res Fremgangsmåde til behandling af cancere, der udtrykker vaskulær endotelvækstfaktor D
WO2001064235A1 (en) * 2000-03-02 2001-09-07 Ludwig Institute For Cancer Research Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor d
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
AU6456501A (en) * 2000-05-03 2001-11-12 Ludwig Inst Cancer Res A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
AU2884102A (en) 2000-12-07 2002-06-18 Sangamo Biosciences Inc Regulation of angiogenesis with zinc finger proteins
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
JP4669984B2 (ja) 2001-01-19 2011-04-13 ベジェニクス リミテッド 腫瘍画像化のターゲットとしてのＦ１ｔ４（ＶＥＧＦＲ−３）および抗腫瘍療法
US20040132675A1 (en) * 2002-02-08 2004-07-08 Calvin Kuo Method for treating cancer and increasing hematocrit levels
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
NZ537579A (en) 2002-06-10 2006-10-27 Vaccinex Inc C35 peptide epitopes and their analogs
WO2005087177A2 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same
ES2363758T3 (es) 2005-08-15 2011-08-16 Vegenics Pty Ltd Vegf y pdgf modificados con propiedades angiogénicas mejoradas.
EP2237792B1 (de) 2007-12-26 2017-05-24 Vaccinex, Inc. Anti-c35-antikörper-kombinationstherapien und verfahren
US20100029491A1 (en) * 2008-07-11 2010-02-04 Maike Schmidt Methods and compositions for diagnostic use for tumor treatment
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011154308A1 (en) 2010-06-08 2011-12-15 Proyecto De Biomedicina Cima, S.L. New compositions and cell therapy methods for the treatment of cirrhosis
EP3693381A1 (de) 2013-02-18 2020-08-12 Vegenics Pty Limited Ligandbindende moleküle und verwendungen davon

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233803D1 (de) 1992-10-28 2011-03-31 Genentech Inc Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten
CN1173991C (zh) 1992-11-13 2004-11-03 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k-1
ATE281469T1 (de) 1993-03-25 2004-11-15 Merck & Co Inc Inhibitor des wachstumsfaktors für gefäss- endothelzellen
ATE280835T1 (de) 1993-09-03 2004-11-15 Chugai Pharmaceutical Co Ltd Apoptose induzierender monoklonaler antikörper
DE69434538T2 (de) * 1994-03-08 2006-08-10 Human Genome Sciences, Inc. Vaskulärer endothelialer Wachstumsfaktor 2
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
EP1382679A3 (de) 1995-09-08 2004-11-10 Genentech, Inc. Antagonisten gegen Vaskuläres Endothelzellen Wachstumsfaktor-verwandtes Protein (VRP)
EP1553182B1 (de) 1995-09-29 2010-03-03 Universita Degli Studi Di Siena Regulierte Gene und ihre Verwendungen
US6828426B1 (en) * 1996-07-15 2004-12-07 Chugai Seiyaku Kabushiki Kaisha VEGF-like factor
DK0956339T3 (da) * 1996-08-23 2006-01-30 Licentia Oy Rekombinant vaskulær endotelcellevækstfaktor D (VEGF-D)
WO1998024811A2 (en) * 1996-12-06 1998-06-11 Zymogenetics, Inc. Vascular endothelial growth factor

Also Published As

Publication number Publication date
EP0935001B2 (de) 2011-08-10
ATE294863T1 (de) 2005-05-15
AU3461097A (en) 1998-02-09
DE69733204T2 (de) 2006-05-11
AU733322B2 (en) 2001-05-10
US6828426B1 (en) 2004-12-07
US20050112665A1 (en) 2005-05-26
DE69733204T3 (de) 2012-03-08
ES2242227T3 (es) 2005-11-01
JP3911028B2 (ja) 2007-05-09
EP0935001B1 (de) 2005-05-04
WO1998002543A1 (fr) 1998-01-22
EP0935001B9 (de) 2007-01-24
US7803576B2 (en) 2010-09-28
EP0935001A4 (de) 2000-08-23
US20060172343A1 (en) 2006-08-03
US20110293602A1 (en) 2011-12-01
ES2242227T5 (es) 2011-12-09
EP0935001A1 (de) 1999-08-11

Similar Documents

Publication Publication Date Title
DE69733204D1 (de) Neuartige vegf-ähnliche faktoren
DK288183A (da) Fremgangsmaade til fremstilling af et oligonucleotidt terapeutisk middel
AU6847298A (en) Transcription factor islet-brain 1 (ib1)
KR830005355A (ko) 박테리아숙주내에서 각종 폴리펩타이드를 합성하는 방법 및 폴리펩타이드 dna
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
EP0814827A4 (de) Wachstumsfaktor-b, spezifisch für vaskuläre endothelzellen
WO2003045316A3 (en) Polynucleotide therapy
WO2003049700A3 (en) Growth hormone releasing hormone suplementation for treating chronically ill subjects
HUP9903921A2 (hu) Tumor nekrózis faktorral rokon ligandum
WO2003023000A3 (en) Linear dna fragments for gene expression
ATE374251T1 (de) Zusammensetzungen zur gentherapie von diabetes
Adas et al. VEGF-A and FGF gene therapy accelerate healing of ischemic colonic anastomoses (experimental study)
ATE229977T1 (de) Peptide mit antiproliferativen eigenschaften
WO1999062561A3 (en) Gene therapy method
ATE88500T1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
IL143516A (en) E3 ubiquitin ligase polypeptide, polynucleotide encoding the same and uses thereof
HUP0002913A2 (hu) Eljárások és készítmények szekretált fehérjéket, például béta-interferont kódoló géneket alkalmazó terápiára
CA2260754A1 (en) Novel vegf-like factor
WO2003016343A3 (en) USE OF αCP1, αCP2, AND HUR FOR MODULATING GENE EXPRESSION AND INDUCING ANGIOGENESIS
ATE447415T1 (de) Ghrh zur verwendung bei der behandlung von chronischer niereninsuffizienz
ATE87977T1 (de) Herstellung menschlichen somatomedins c.
WO2003068954A8 (de) Mikroorganismus zur gentherapeutischen behandlung proliferativer erkrankungen
WO1998012220A3 (en) Novel tumor proteins
WO2000005416A3 (en) Fgf-bp promoter sequences as sensors of drug effects

Legal Events

Date Code Title Description
8363 Opposition against the patent
R102 Epo decision maintaining patent in amended form now final

Ref document number: 935001

Country of ref document: EP

Effective date: 20110810